Welcome to our dedicated page for AVALYN PHARMACEUTICALS news (Ticker: AVLN), a resource for investors and traders seeking the latest updates and insights on AVALYN PHARMACEUTICALS stock.
Avalyn Pharma Inc. reports news about its clinical-stage development of inhaled therapies for serious, rare respiratory diseases. Recurring company updates cover AP01 and AP02, pulmonary fibrosis research, clinical presentations, peer-reviewed publications, patient-centered treatment research, and respiratory-disease conference activity.
Company news also includes public-company developments such as the closing of its initial public offering, Nasdaq listing of AVLN common stock, capital-structure updates, governance changes, leadership appointments, clinical or regulatory disclosures, and operating and financial results tied to its rare lung disease pipeline.
Avalyn (NASDAQ:AVLN) appointed Jon Congleton to its Board of Directors on April 6, 2026. Congleton brings nearly 40 years of biopharma experience and current CEO experience at Mineralys, with expertise in commercial strategy and organizational leadership.
His appointment is positioned to support Avalyn's Phase 2 programs, MIST for AP01 and AURA for AP02, and preparation for late‑stage development and commercialization.
Avalyn (NASDAQ:AVLN) announced a peer-reviewed publication (BMC Pulmonary Medicine, March 25, 2026) reporting that quantitative HRCT imaging changes with inhaled AP01 (pirfenidone) correlated with lung function and quality-of-life improvements in Phase 1b ATLAS patients.
Key results: >70% of AP01 100 mg BID patients with baseline and Week 24 imaging showed stabilization or improvement in fibrosis score; QOL gains appeared by Week 8 and persisted to Week 48. Avalyn plans HRCT in upcoming Phase 2 MIST and AURA trials; additional longitudinal data expected mid-2026.